VTCN1 and breast cancer: In our experimental setup, MDA‐MB‐468 breast cancer cells exposed to SG in addition to other DNA damaging agents showed increased levels of both USP10 and B7‐H4 (Figure 6C and Figure S6D, Supporting Information), suggesting that SG and other DNA‐damaging agents, including those used in systemic chemotherapy, may contribute to an immune‐suppressive milieu governed by B7‐H4.